No. 21-1342
Jacobus Pharmaceutical Company, Inc. v. Catalyst Pharmaceuticals, Inc., et al.
Tags: administrative-law circuit-split drug-exclusivity fda fda-regulation lambert-eaton-myasthenic-syndrome orphan-drug-act rare-disease statutory-interpretation
Latest Conference:
N/A
Question Presented (from Petition)
Does the ODA unambiguously foreclose FDA's decades-long, consistent interpretation that the scope of orphan-drug exclusivity is tied to a drug's approved use?
Question Presented (AI Summary)
Does the Orphan Drug Act unambiguously foreclose FDA's interpretation that the scope of orphan-drug exclusivity is tied to a drug's approved use?
Docket Entries
2022-07-22
Petition Dismissed - Rule 46.
2022-07-13
Joint stipulation for dismissal of the petition for a writ of certiorari pursuant to Rule 46 filed.
2022-07-11
Brief of Federal Respondents in opposition filed.
2022-05-31
Motion to extend the time to file a response is granted and the time for Catalyst Pharmaceuticals, Inc. to file a response is further extended to and including July 25, 2022.
2022-05-27
Motion of Catalyst Pharmaceuticals, Inc. to extend the time to file a response from June 24, 2022 to July 25, 2022, submitted to The Clerk.
2022-05-26
Motion to extend the time to file a response is granted and the time is further extended to and including July 11, 2022, for all respondents.
2022-05-25
Motion of the Solicitor General to extend the time to file a response from June 10, 2022 to July 11, 2022, submitted to The Clerk.
2022-05-23
Motion to extend the time to file a response is granted and the time for Catalyst Pharmaceuticals, Inc. to file a response is extended to and including June 24, 2022.
2022-05-20
Motion of Catalyst Pharmaceuticals, Inc. to extend the time to file a response from June 10, 2022 to June 24, 2022, submitted to The Clerk.
2022-05-05
Motion to extend the time to file a response is granted and the time is extended to and including June 10, 2022, for all respondents.
2022-05-04
Motion to extend the time to file a response from May 11, 2022 to June 10, 2022, submitted to The Clerk.
2022-04-07
Petition for a writ of certiorari filed. (Response due May 11, 2022)
Attorneys
Catalyst Pharmaceuticals, Inc.
Philip J. Perry — Latham & Watkins, LLP, Respondent
Jacobus Pharmaceutical Company, Inc.
Marisa Christina Maleck — King & Spalding LLP, Petitioner
Xavier Becerra, Secretary of Health and Human Services, et al.
Elizabeth B. Prelogar — Solicitor General, Respondent